SCHEMBL2174329

SCHEMBL2174329

COCOCCc1ccc(C(O)c2cc(Br)c(OCc3ccccc3)cc2C)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.36
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ABCB1 P08183 3/20 0.33
BCHE P06276 2/20 0.33
FFAR1 O14842 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
C5AR1 P21730 1/20 0.32
MAPT P10636 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172572 0.89 SMN1; SMN2 (0.34) FFAR4RAB9ASMN1; SMN2ABCB1BCHE
SCHEMBL3223738 0.83 SMN1; SMN2 (0.39) FFAR4KEAP1NFE2L2RAB9ASMN1; SMN2
SCHEMBL2172626 0.81 ABCB1 (0.39) FFAR4RAB9ASMN1; SMN2ABCB1HTR2A
SCHEMBL21557913 0.80 LMNA (0.44) KEAP1NFE2L2RAB9ASMN1; SMN2FFAR1
SCHEMBL3223036 0.79 RAB9A (0.38) FFAR4KEAP1NFE2L2RAB9ASMN1; SMN2
SCHEMBL21551795 0.79 MAPT (0.42) KEAP1NFE2L2RAB9ASMN1; SMN2MAPT
SCHEMBL6809786 0.77 RAB9A (0.46) FFAR4RAB9ASMN1; SMN2ABCB1FFAR1
SCHEMBL20140068 0.76 HTR2A (0.42) FFAR4KEAP1NFE2L2RAB9ASMN1; SMN2
SCHEMBL12407955 0.76
SCHEMBL14384679 0.75 GLA (0.36) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076503-B1 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-07-17 EP disclosed
US-7973012-B2 C-phenyl glycitol compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-07-05 US disclosed
US-20100022460-A1 C-PHENYL GLYCITOL COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-01-28 US disclosed
EP-2076503-A2 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-07-08 EP disclosed
WO-2007136116-A2 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022460-A1 C-PHENYL GLYCITOL COMPOUND SLC5A1, SLC5A2, SLC2A1 FFAR4 1656/4885KEAP1 555/4885NFE2L2 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.